1-year Follow-Ups and Top-Line Clinical Results from ARTISAN-SNM Pivotal Clinical Study

HRS Scientific Sessions: Boston Scientific LBCT

During the Heart Rhythm Scientific Sessions this week, Boston Scientific announced positive LBCT data underscoring the safety and efficacy of multi-site pacing (MSP) over conventional cardiac resynchronization therapy (CRT), as well as poster presentations on real-world use of the WATCHMAN Left Atrial Appendage Closure (LAAC) device and next-generation WATCHMAN FLX LAAC device as alternatives to oral anticoagulation therapy for stroke risk reduction in patients with non-valvular atrial fibrillation.

What are the Most Commonly Performed Surgeries?

Whether you are trying to learn more about a surgery you are planning to have or find out what the most common procedures are, this list is here for you. Read more.

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing a novel implantable Sacral Neuromodulation (“SNM”) device for the treatment of urinary and bowel dysfunction, today announced completion of 1-year follow-ups and top-line clinical results from its ARTISAN-SNM pivotal clinical study conducted under an U.S. Food & Drug Administration (“FDA”) Investigational Device Exemption (“IDE”) designed to evaluate the safety and efficacy of the Axonics r-SNM® System1.

The study results at 1-year demonstrate that patients implanted with the Axonics r-SNM System continue to receive clinically meaningful and statistically significant improvements in urinary urgency incontinence symptoms and quality of life.

At 1-year, 89% of all implanted subjects were therapy responders, consistent with the 90% therapy responder rate reported at 6-months. There were no serious adverse device related events or unanticipated device related events. The results at 1-year show consistent symptom decrease, quality of life improvement, and patient satisfaction as the previously reported 6-month study results.

Karen Noblett, M.D., Chief Medical Officer of Axonics said, “The responder rate from the ARTISAN-SNM study is the highest success rate reported in SNM literature and confirms sustained efficacy. Analyzing all implanted subjects is the most rigorous form of data analysis and makes the results that much more impressive.”

Detailed study results are planned to be presented at the American Urogynecologic Society (AUGS), International Urogynecological Association (IUGA) congress being held from September 24 – 28, 2019 in Nashville.

ARTISAN-SNM: 1-Year Responder Rate

The ARTISAN-SNM study is a 129-patient single-arm, prospective, multi-center, unblinded pivotal clinical study to evaluate the safety and efficacy of the Axonics r-SNM System. The study was conducted in 14 centers in the U.S. and five centers in Western Europe. All patients diagnosed with urinary urge incontinence were implanted with a tined lead and the Axonics miniaturized rechargeable neurostimulator in a non-staged procedure. Efficacy data was collected using a 3-day bladder diary, a validated quality of life questionnaire (ICIQ-OABqol), and a subject satisfaction questionnaire. Therapy responders at follow-up were identified as patients with at least a 50% reduction in urinary urgency incontinence episodes compared to baseline. An as-treated analysis was performed for all patients. At 1-year, 89% of all implanted subjects were therapy responders.


Reference

1 The Axonics r-SNM System is currently under PMA review by the FDA and designated as an investigational medical device

spot_img

DON'T MISS

Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.